Trials of prostate-cancer screening are not worthwhile.


About 3% of men in developed countries die from prostate cancer. No conclusive evidence, however, either supports or refutes the benefit of prostate-cancer screening. More than 200 000 participants are needed for a screening study with prostate-cancer-specific death as the endpoint. A relative reduction in prostate-cancer mortality of 25% leads to a decrease in absolute risk of less than 1%-a difference of 75 individuals between the control and screening group. Participant non-compliance and small inaccuracies in attributing cause of death need to be compensated for in study size, requiring several million participants. Screening trials with insufficient sample sizes might show a lowering of cancer-specific mortality but not detect increases in all-cause mortality related to screening. Studies of a manageable size have too little discriminatory power and last a long time. Furthermore, results become available decades after trial initiation, by which time they are probably antiquated. Whether screening for prostate cancer is beneficial cannot be assessed in trials, a statement that might also be true for other diseases with low specific mortality.

DOI: 10.1016/S1470-2045(09)70066-X


Citations per Year

96 Citations

Semantic Scholar estimates that this publication has 96 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Dubben2009TrialsOP, title={Trials of prostate-cancer screening are not worthwhile.}, author={H. H. Dubben}, journal={The Lancet. Oncology}, year={2009}, volume={10 3}, pages={294-8} }